The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Cardiovascular disease is the leading cause of death in women. Decades of grassroots
campaigns have helped to raise awareness about the impact of cardiovascular disease in …

Heart failure is a global pandemic affecting an estimated 26 million people worldwide and
resulting in more than 1 million hospitalizations annually in both the United States and Europe…

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization
for heart failure and cardiovascular death among patients with chronic heart failure …

… As diagnostic tests have rarely been subject to randomized controlled trials (RCTs), most of
the evidence would be regarded as level C. However, that does not mean that there has not …

Background Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, but their effects in …

This randomized, controlled trial assessed the efficacy of transarterial Lipiodol (Lipiodol
Ultrafluide, Laboratoire Guerbet, Aulnay-Sous-Bois, France) chemoembolization in patients with …

… In accordance with the World Health Organization (WHO), our case definition was a fever
(temperature >38C), a chest radiograph or computed tomographic image of the thorax showing …

Background Alterations in circulating soluble fms-like tyrosine kinase 1 (sFlt1), an antiangiogenic
protein, and placental growth factor (PlGF), a proangiogenic protein, appear to be …

… The mixtures were amplified with 60 cycles of 94C for 1 min, 48C for 1 min, and 72C for 1
min and a final extension at 72C for 10 min in an automated thermal cycler (Applied Biosystems…